TY  - GEN
AU  - Italiano,Antoine
AU  - Soria,Jean-Charles
AU  - Toulmonde,Maud
AU  - Michot,Jean-Marie
AU  - Lucchesi,Carlo
AU  - Varga,Andrea
AU  - Coindre,Jean-Michel
AU  - Blakemore,Stephen J
AU  - Clawson,Alicia
AU  - Suttle,Benjamin
AU  - McDonald,Alice A
AU  - Woodruff,Mark
AU  - Ribich,Scott
AU  - Hedrick,Eric
AU  - Keilhack,Heike
AU  - Thomson,Blythe
AU  - Owa,Takashi
AU  - Copeland,Robert A
AU  - Ho,Peter T C
AU  - Ribrag,Vincent
TI  - Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
SN  - 1474-5488
PY  - 2019///0409
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Benzamides
KW  - Biphenyl Compounds
KW  - Dose-Response Relationship, Drug
KW  - Enhancer of Zeste Homolog 2 Protein
KW  - antagonists & inhibitors
KW  - Enzyme Inhibitors
KW  - Female
KW  - France
KW  - Humans
KW  - Lymphoma, B-Cell
KW  - drug therapy
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Morpholines
KW  - Pyridones
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(18)30145-1
ER  -